Glioblastoma: all 1,951 studies

Page 19 of 20. Open to participants first (457), then studies with results posted, then the rest; newest registration first within each.

• Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant GlioblastomasCompletedNCT00463073Phase 2
• Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma MultiformeCompletedNCT00458601Phase 2
• Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade GliomaCompletedNCT00431561Phase 2
• Radiotherapy for Malignant Astrocytomas in the ElderlyCompletedNCT00430911Phase 3
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant GliomaTerminatedNCT00430079Not applicable
• Epothilone ZK-219477 in Treating Patients With Recurrent GlioblastomaCompletedNCT00424060Phase 2
• Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of GliomaCompletedNCT00409214Phase 2
• Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) InfectionCompletedNCT00400322Not applicable
• Epothilone in Recurrent Glioblastoma PatientsCompletedNCT00397072Phase 2
• AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma MultiformeStatus unknownNCT00394628Phase 1/2
• URINARY VEGF Levels in GBM Patients on Radiation Treatment ProtocolStatus unknownNCT00392548
• Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00390403Phase 1
• Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma MultiformeCompletedNCT00387400Phase 1
• PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic DrugsCompletedNCT00385853Phase 1
• Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)CompletedNCT00379470Phase 3
• Radiation Boost for Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00376103Phase 1/2
• Phase II Study of Temozolomide in Newly Diagnosed GlioblastomaTerminatedNCT00365222Phase 2
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00362921Phase 2
• A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)CompletedNCT00345163Phase 2
• A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)CompletedNCT00337883Phase 2
• Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)CompletedNCT00335075Phase 3
• Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00331526Phase 2
• Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00316849Phase 1
• Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)Status unknownNCT00311857Phase 1/2
• Safety and Efficacy Study of Panzem NCD to Treat GlioblastomaCompletedNCT00306618Phase 2
• AZD2171 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00305656Phase 2
• Enzastaurin Versus Lomustine in GlioblastomaCompletedNCT00295815Phase 3
• Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00274833Phase 2
• Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to ChemotherapyTerminatedNCT00272870Phase 1
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Safety and Efficacy of Talampanel in Glioblastoma MultiformeCompletedNCT00267592Phase 2
• Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational ResearchCompletedNCT00250887Phase 2
• Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and TemozolomideCompletedNCT00250211Phase 1/2
• Photodynamic Therapy in the Treatment of Malignant Intracranial TumorsWithdrawnNCT00243490Phase 2
• A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma MultiformeCompletedNCT00238797Phase 2
• Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00238277Phase 2
• Erlotinib in Treating Patients With Progressive Glioblastoma MultiformeTerminatedNCT00227032Phase 1
• Chloroquine for Treatment of Glioblastoma MultiformeCompletedNCT00224978Phase 3
• Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma MultiformeCompletedNCT00209989Phase 2
• Randomized Phase 2 With CpG-ODN in Malignant GlioblastomaCompletedNCT00190424Phase 2
• A Phase I/II Study of the Photon Radiosurgery SystemCompletedNCT00179907Phase 1/2
• Stem Cell Transplant for High Risk Central Nervous System (CNS) TumorsCompletedNCT00179803Phase 2
• Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)TerminatedNCT00171938Phase 2
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
• ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid TumorsCompletedNCT00132158Phase 1
• Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00128700Phase 1/2
• Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00128635Phase 1
• Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)CompletedNCT00116376Phase 1/2
• Boron Neutron Capture Therapy (BNCT) as Treatment of GlioblastomaTerminatedNCT00115453Phase 1/2
• BNCT to Treat Glioma That Has Progressed Following RadiotherapyCompletedNCT00115440Phase 1/2
• 131-I-TM-601 Study in Adults With Recurrent High-Grade GliomaStatus unknownNCT00114309Phase 2
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma MultiformeCompletedNCT00107237Phase 1/2
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain TumorsCompletedNCT00104091Phase 2
• Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with TemozolomideActive, not recruitingNCT00102648Phase 1
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
• Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00099125Phase 2
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant GliomaCompletedNCT00089427Phase 1
• Comparison of TransMID vs Standard Treatment of Cancerous Brain TumorsCompletedNCT00088400Phase 3
• Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)CompletedNCT00087451Phase 1
• Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00086879Phase 2
• Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma MultiformeWithdrawnNCT00083447Phase 3
• High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00082797Phase 2
• A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant GliomasCompletedNCT00080054Phase 1
• The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma MultiformeCompletedNCT00076986Phase 3
• Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma MultiformeTerminatedNCT00075491Phase 2
• Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade GliomasCompletedNCT00074646Phase 1
• Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain TumorsCompletedNCT00071539Phase 2
• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaCompletedNCT00070525Phase 2
• Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma MultiformeCompletedNCT00068952Phase 3
• Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant GliomaCompletedNCT00064779Phase 1
• Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
• Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade GliomasTerminatedNCT00062504Phase 2
• Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00058097Phase 2
• Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma MultiformeStatus unknownNCT00054496Phase 2
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00053183Phase 1
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1
• Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic AstrocytomaStatus unknownNCT00052624Phase 1
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00052208Phase 1/2
• Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00049387Phase 1
• Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00047294Phase 2
• Sirolimus in Treating Patients With Glioblastoma MultiformeCompletedNCT00047073Phase 1/2
• Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma MultiformeWithdrawnNCT00046878Phase 2
• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerStatus unknownNCT00045968Phase 3
• Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT00045565Phase 1
• Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00041587Phase 1/2
• Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the BrainCompletedNCT00039572Phase 1/2
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCompletedNCT00039494Phase 2
• Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation TherapyCompletedNCT00039468Phase 2
• Temozolomide and SCH66336 for Recurrent Glioblastoma MultiformeCompletedNCT00038493Phase 2
• Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the BrainCompletedNCT00032097Phase 1
• Genetic Analysis of Brain TumorsTerminatedNCT00031538
• Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV GliomasCompletedNCT00031083Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Efficacy of Distant Healing in Glioblastoma TreatmentCompletedNCT00029783Phase 2

← Glioblastoma overview